Abstract. Recently, the newly determined interleukin (IL)-22-producing T-helper (Th) 22 cell has been implicated to be involved in the pathogenesis of autoimmune diseases. However, its role in the pathogenesis of dilated cardiomyopathy (DCM) has yet to be elucidated. A total of 30 patients with DCM and 30 healthy controls were enrolled in the present study. The levels of Th22, Th17 and Th1 cells in the peripheral blood were analyzed by flow cytometry. Levels of plasma IL-22 and autoantibody adenine nucleotide translocator (ANT) were assessed using the ELISA. The key transcription factor of Th22, aryl hydrocarbon receptor (AHR), was assessed using quantitative polymerase chain reaction. Additionally, clinical data on the brain natriuretic peptide (BNP), C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were collected. In comparison with those in the control group, significantly elevated levels of Th22, Th17 and Th1 cells were detected in patients with DCM (all P<0.01). Similarly, elevated mRNA levels of peripheral AHR were detected in patients with DCM. The percentage of Th22 cells was higher in ANT-positive compared with ANT-negative patients with DCM. The levels of BNP and CRP, but not ESR, showed a significant positive correlation with those of Th22 cells. With regard to the concentrations of plasma IL-22, no statistical difference was found between patients with DCM and the healthy controls, nor did it demonstrate a statistical correlation with the percentage of Th22 cells. In conclusion, the present study showed that patients with DCM, particularly those of the ANT autoantibody positive subjects, exhibit elevated levels of peripheral Th22 cells, indicating that a Th22 immune response may be implicated in the pathogenesis of DCM.
Introduction
Dilated cardiomyopathy (DCM), the most common of the cardiomyopathies and is characterized by the progressive deterioration of myocardial contractile function and ventricular dilation (1, 2) . The five-year survival rate following diagnosis is 50%, as patients often develop progressive congestive heart failure and complications, including thromboembolic conditions and arrhythmias (2, 3) . Although it has been described that the dysregulation of T-cells, including T helper (Th) 1 cells, Th2, Th17 and regulatory T-cells, have a critical role in the autoimmune response of DCM (4) (5) (6) (7) , with the discovery of the anti-heart antibodies, including the autoantibody against the adenine nucleotide translocator (ANT) (8) , the pathophysiology of DCM remains to be fully elucidated.
Th22 cells are a novel subset of T cells clearly separated from other known Th cells. Th22 is distinct from interleukin (IL)-17-secreting and retinoic acid receptor-related orphan receptor γt-regulated Th17, interferon (IFN)-γ-secreting and T-bet-regulated Th1 or IL-4-secreting and trans-acting T-cell-specific transcription factor GATA-3-regulated Th2 cells. Th22 is characterized by producing abundant cytokine IL-22 and is regulated by the key transcription factor aryl hydrocarbon receptor (AHR) and other cytokines, including tumor necrosis factor-α and IL-6 (9, 10) . Excluding the chemokine receptor C-C chemokine receptor (CCR) type 10, Th22 shares common surface markers with Th17 cells, including CCR6 and CCR4. In previous years, studies have focused on the participation of Th22 cells in various human inflammatory disorders and immune-mediated tissue injury, including rheumatoid arthritis, Crohn's disease and systemic sclerosis. The elevation of circulating Th22 cells was positively correlated with the levels of autoimmune antibodies, Th17, Th1 cells and the severity of several diseases (11) (12) (13) (14) (15) . Up to date, the involvement of IL-22 in DCM has remained to be elucidated and no data exist with regard to Th22 cells and their association with Th17 or Th1 in patients with DCM.
In the present study, the percentages of peripheral Th22, Th17 and Th1, the expression of AHR in peripheral blood mononuclear cells (PBMCs) as well as the levels of IL-22, ANT, brain natriuretic peptide (BNP), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in the peripheral blood of patients with DCM were measured, and their relevance was evaluated.
Materials and methods
Patients and controls. The study included 60 individuals, comprising 30 cases with primary DCM and 30 normal individuals (controls) and was conducted between December 2010 and February 2013. Primary DCM was diagnosed based on the guidelines of the World Health Organization (1). Accordingly, various secondary causes of heart failure, including coronary artery disease and valvular diseases, were excluded in order to diminish the potential confounding effects of etiological heterogeneity of heart failure. A control group of normal individuals, defined as asymptomatic age-and gender-matched individuals with normal electrocardiograms and echocardiograms, was included. A normal echocardiogram excluded the diagnosis of DCM in the control individuals. Patients who were receiving anti-inflammatory or immunosuppressive medications, recently treated with antibiotics and other underlying acute or chronic diseases, were all excluded from the present study. To reduce the potential confounding effects of diabetes mellitus, those who had this disease were excluded. The present study was performed in accordance with protocols approved by the Guangxi Medical University Ethics Committee (Guangxi, China) and the participants gave informed consent. The clinical data, including ESR and CRP were also collected. The characteristics of the study subjects are summarized in Table Ⅰ .
Isolation and stimulation of PBMCs. Peripheral blood was harvested with 50 U/ml heparin and diluted with an equal volume of phosphate-buffered saline. PBMCs were isolated using Ficoll-Plaque (Solarbio Science & Technology, Beijing, China) by gradient centrifugation at 300 x g and cells were resuspended with a final concentration of 2x10 6 in complete RPMI-1640 (Solarbio Science & Technology) supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin, followed by incubation at 37˚C with 5% CO 2 for 5 h in the presence of 25 ng/ml phorbol myristate acetate (PMA) 1 µg/ml ionomycin (both from Sigma-Aldrich, St. Louis, MO, USA) and Golgi Plug (1 µl/10 6 cells; BD Biosciences, San Diego, CA, USA). 
Flow cytometric analysis.

AHR mRNA expression by quantitative-polymerase chain reaction (qPCR).
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was used to isolate the total RNA of PBMCs. The RNA was transcribed into cDNA with a reverse transcription kit (Ferma, Mountain View, CA, USA) according to the manufacturer's instructions. qPCR was performed for AHR and the housekeeping gene β-actin on an ABI 7500 Real-Time PCR System (Applied Biosystems, Grand Island, NY, USA) using SYBR ® Green. The PCR reactions were cycled 40 times following initial denaturation at 94˚C for 3 min with ANT assessment by ELISA. For the qualitative determination of human ANT autoantibody concentrations in serum, an ANT autoantibody ELISA kit was used according to manufacturer's instructions (cat no. CSB-EQ027458HU; Cusabio, Wuhan, China). In order to calculate the valence of the human ANT autoantibody, the sample well was compared with the control. A cutoff value was defined as the average negative control value plus 0.2. An optical density (OD) sample < the cutoff value was negative, while an OD sample ≥ the cut off value was positive.
Statistical analysis. Quantitative variables were expressed as the mean ± standard deviation. Differences between two groups were determined using the Newman-Keuls multiple comparison test (q-test). The Pearson's or Spearman's correlation test was used for correlation analysis depending on the data distribution. Qualitative variables of ANT were expressed as percentages and differences in ANT distribution between groups were obtained using the χ 2 test. Analysis was performed using SPSS version 17.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference. (Fig. 2B) . Similarly, the percentages of the Th17 cells were profoundly increased in the DCM group (2.27±0.59%) as compared with the control group (0.27±0.07%; P<0.01) (Fig. 2C) .
Results
Elevated circulating
Positive correlation between Th22 and Th17 cells in DCM.
Correlations between the frequencies of Th22, Th17 and Th1 cells in patients with DCM were examined. There was a significant positive correlation between numbers of Th22 and Th17 cells, as shown in Fig. 2D (r=0.676 and P<0.001) . However, the correlation analysis between the percentages of Th1 and Th22 cells showed no significant association in patients with DCM (r=0.326 and P=0.052) (Fig. 2E) .
Enhanced mRNA expression of peripheral AHR in DCM.
The mRNA expression of AHR, the key transcription factor directing Th22 lineage commitment, was determined by (Fig. 2F) .
Plasma levels of IL-22.
Plasma levels of IL-22 were evaluated by ELISA. Of note, the expression of IL-22 did not differ between patients with DCM and healthy controls (19.78±5.9 vs. 21.3±5.4 pg/ml; P=0.303) (Fig. 3A) . Furthermore, no significant correlation was identified between Th22 cells and IL-22 levels (r=0.345 and P=0.061; Fig. 3B ), nor between Th17 cells and IL-22 (r=0.235 and P=0.211; Fig. 3C ). As shown in Fig. 3D , the peripheral Th1 cells did not show a statistical correlation with circulating levels of IL-22 (r=0.221 and P=0.241). 
Th22 cells but not IL-22 levels are increased in ANT
Discussion
The identification of Th17 and Th22 cells as distinct subsets of CD4 + T cells has extended the Th1/Th2 paradigm in autoimmune and inflammatory diseases (11) (12) (13) (14) (15) . However, to date, no studies have directly assessed the presence of circulating Th22 cells in patients with DCM. By applying a multi-parameter cytofluorimetric analysis, the present study revealed that there were significantly increased frequencies of Th22 cells in patients with DCM as compared with healthy controls. In parallel, an elevated expression of AHR, the key transcription factor for Th22-cell differentiation, was observed in the DCM group. These data indicated that an enhanced Th22-cell response may participate in the pathogenesis of DCM. Of note, a previous study by our group reported elevated levels of Th22 cells in viral myocarditis (VMC) (16) , a disease which may evolve into DCM (2, 3, 17) . Thus, whether higher levels of Th22 cells are involved in the evolvement from VMC to DCM, is an interesting unsettled question. It should be mentioned that the levels of Th22 cells identified in the present study appear to differ from those in other reports (13, 15) . It is hypothesized that these discrepancies may be due to different conjugated anti-human-specific antibodies used in the flow cytometric analysis. Furthermore, the enrichment of Th22 cells was closely associated with elevated levels of Th17 cells, indicating a polyfunctional cytokine profile and a potentially synergistic function of CD4 + T cells in patients with DCM. ANT is an autoantibody against the adenosine diphosphate/adenosine triphosphate carrier. A higher frequency of Th22 cells was found in ANT antibody-positive patients with DCM as compared with those in negative subjects. Given that ANT production may have been induced by a loss of tolerance to cardiac self-antigens and is capable of cross-reacting with subunits of the calcium channel on the cardiac cell membrane, which results in myocardial cytotoxic injury (18, 19) , the findings of the present study indicated that the Th22 response may be involved in organ-specific autoimmunity and myocardial injury in patients with DCM. In addition, a positive correlation was identified between the proportions of Th22 cells and the values of CRP, a significant inflammatory marker and independent predictor of future cardiovascular events (20, 21) . Furthermore, there was a positive correlation between the percentages of Th22 cells and the levels of BNPs, which are predominantly secreted by cardiac myocytes in response to stretching forces (22, 23) . BNPs have been demonstrated to be powerful predictors of mortality and major adverse cardiovascular events in patients with DCM (22) (23) (24) (25) . Thus, these observations implied that Th22 cells may be one predictor for cardiac events in DCM, but further research with larger subjects and a long-term follow-up are warranted.
IL-22 is the most significant functional cytokine of Th22 cells and positive correlations have been observed between elevated levels of IL-22 and Th22 cells in various types of autoimmune diseases (11) (12) (13) (14) (15) 26, 27) . The present study observed higher levels of Th22 cells in patients with DCM, and unexpectedly, the plasma levels of IL-22 were comparable between the DCM and control group. Furthermore, IL-22 levels did not show a statistically significant difference between ANT-positive and -negative patients with DCM. In addition, plasma concentrations of IL-22 did not show a statistically significant correlation with the percentage of Th22 cells, nor did the Th17 and Th1 cells. The results of the present study were discrepant with previous observations (11) (12) (13) (14) (15) 26, 27) , which may be due to different biological characteristics among different autoimmune disorders, indicating that Th22 cells are not the major producer of IL-22 in DCM. IL-22 may be produced by various cell types in the microenvironment of DCM, including innate lymphoid cells, natural killer and γδ T cells, but production is not limited to Th22, Th1 and Th17 cells (28) (29) (30) .
Principal limitations of the present study are the small sample size, observations made at only one time-point and single blood sampling. Furthermore, due to the limited number of subjects with DCM, a definitive causal correlation between the Th22 cells and New York Heart Association (NYHA) func- A B C tional impairment was not identified. In addition, the subjects of the present study were primarily comprised of men; thus, these results may not necessarily apply to women. Further prospective studies enrolling larger cohorts of patients are required to further elucidate the pathophysiological function and prognostic role of Th22 cells in patients with DCM.
In conclusion, the present study demonstrated an elevation of Th22 cells in patients with DCM, particularly in ANT autoantibody-positive subjects. These novel findings imply that the Th22 response may participate in the pathogenesis of DCM. Further studies in a larger sized population are required to validate these findings and to determine the role of Th22 in the immunopathogenesis of DCM.
